Table 5.
MAF values of KRAS mutational status at the baseline and during treatment, type of therapy, and response in mCRC patients enrolled in the study. M: mutated; WT: wild type; END: end of the study; PR: partial response; PD: progressed disease; CR: complete response; SD: stable disease.
| Baseline | 4 Weeks | 8 Weeks | 12 Weeks | 48 Weeks | Therapy | Best Response | |
|---|---|---|---|---|---|---|---|
| Oncobio001 | M (0.042) | Low DNA | M (0.340) | M (0.418 + 0.156 Cd61) | END | FOLFIRI + BEVACIZUMAB | PD |
| Oncobio002 | M (0.173) | WT (0.010) | M (0.127) | FOLFIRI + BEVACIZUMAB | SD | ||
| Oncobio003 | M (0.012) | M (0.254) | Low DNA | FOLFIRI | CR | ||
| Oncobio004 | M (7.103) | Low DNA | M (0.604) | XELOX | PR | ||
| Oncobio005 | M (0.060) | M (0.530) | M (0.082) | CAPOX + BEVACIZUMAB | PR | ||
| Oncobio006 | Low plasma vol | Low DNA | XELOX | SD | |||
| Oncobio007 | WT (0.005) | WT (0.006) | M (0.102) | FOLFOX + VECTIBIX | PR | ||
| Oncobio008 | WT (0.010) | M (0.105) | Low plasma vol | 0.011 | FOLFIRI + VECTIBIX | SD | |
| Oncobio009 | WT (0.005) | WT (0.010) | M (0.503) | FOLFIRI + VECTIBIX | SD | ||
| Oncobio010 | M (0.012) | M (0.040) | END | CAPOX + BEVACIZUMAB | PD | ||
| Oncobio011 | M (0.233) | M (0.038) | M (0.451) | CAPECITABINE + PANITUMUMAB | SD | ||
| Oncobio012 | M (0.771) | END | CAPOX | PD | |||
| Oncobio013 | M (8.159) | M (0.382) | END | FOLFOXIRI | PD | ||
| Oncobio014 | Low plasma vol | Low plasma vol | M (0.218) | M (1.995) | CAPOX + BEVACIZUMAB | SD | |
| Oncobio015 | WT (0.010) | END | CAPOX + BEVACIZUMAB | PD | |||
| Oncobio016 | WT (0.005) | M (0.050) | WT (0.011) | FOLFIRI + BEVACIZUMAB | |||
| Oncobio017 | M (0.334) | M (0.461 + 0.065 Cd117) | FOLFOX | ||||
| Oncobio018 | Low plasma vol | M (0.251) | M (0.290) | END | FOLFIRI + BEVACIZUMAB | PD | |
| Oncobio019 | M (0.317) | M (0.351) | M (0.242) | CAPECITABINE + BEVACIZUMAB | |||
| Oncobio020 | M (0.026) | M (0.045) | M (0.137) | END | CAPOX + BEVACIZUMAB | PD | |
| Oncobio021 | M (0.038 + 0.056 NRAS Cd12) |
M (0.054) | Low plasma vol | END | CAPOX + BEVACIZUMAB | PD | |
| Oncobio022 | M (0.437) | M (0.112) | Low DNA | CAPOX + BEVACIZUMAB | SD | ||
| Oncobio023 | M (0.393) | M (0.110) | M (0.017) | FOLFOX | PR | ||
| Oncobio024 | WT (0.003) | M (0.018) | WT (0.008) | OXALIPLATIN | PR | ||
| Oncobio025 | M (0.162) | M (0.063) | DEGRAMONT + BEVA | ||||
| Oncobio026 | Low plasma vol | Low plasma vol | Low plasma vol | CAPECITABINE + BEVACIZUMAB | |||
| Oncobio027 | M (1.004) | Low plasma vol | M (1.044) | END | FOLFOX + BEVACIZUMAB | PD | |
| Oncobio028 | Low plasma vol | M (0.015) | M (0.038) | FOLFOX | |||
| Oncobio029 | M (0.218) | WT (0.005) | END | PEMBROLIZUMAB | PD | ||
| Oncobio030 | M (3.102) | M (0.358 + 0.047 NRAS Cd12) | |||||
| Oncobio031 | M (0.021) | M (0.012) | WT (0.008) | FOLFIRI + BEVACIZUMAB | |||